Assistant Professor, Pathology, Ohio State University College of Medicine

Pathology

Dr. Weiqiang Zhao works in the field of Pathology. He studied medicine at Hunan Medical University. Weiqiang Zhao is also a published doctor. He has 28 publication published. The most recent publication is: Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. He accepts Medicare.

Publications

---

• Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
• CT Gray-Level Texture Analysis as a Quantitative Imaging Biomarker of Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma of the Lung.
• Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia.
• Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
• From single-gene to multiplex analysis in lung cancer, challenges and accomplishments: a review of a single institution's experience.
• Peroxisome proliferator-activated receptor γ1 and γ2 isoforms alter lipogenic gene networks in goat mammary epithelial cells to different extents.
• Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.
• Y-chromosome status identification suggests a recipient origin of posttransplant non-small cell lung carcinomas: chromogenic in situ hybridization analysis.
• Erlotinib in African Americans with Advanced Non-Small Cell Lung Cancer: A Prospective Randomized Study with Genetic and Pharmacokinetic Analysis.
• DDB2 Suppresses Tumorigenicity by Limiting the Cancer Stem Cell Population in Ovarian Cancer.
• Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.
• Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
• Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
• DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells.
• A phase I trial of flavopiridol in relapsed multiple myeloma.
• Left-sided sessile serrated polyps/adenomas-reply.
• Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
• Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab cons...
• Prolapse-related changes are a confounding factor in misdiagnosis of sessile serrated adenomas in the rectum.
• Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.
• Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma.
• A Novel Role of CYP2E1 in Human Megakaryocyte Development.
• Clinical and Metabolic Parameters in Non-Small Cell Lung Carcinoma and Colorectal Cancer Patients with and without KRAS Mutations.
• Increased NQO1 but Not c-MET and Survivin Expression in Non-Small Cell Lung Carcinoma with KRAS Mutations.
• Inter-reader variability in follicular lymphoma grading: Conventional and digital reading.
• Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease.
• Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.

Schools

---

• Hunan Medical College

Doctors Specialties

---

• Anatomic Pathology
• Pathology

Accepted Insurances

---

• Aetna
• CareSource
• Cigna
• Commercial Insurance Company
• CoreSource
• Coventry Health America PPO
• First Health (Coventry Health Care) PPO
• Frontpath Health Coalition
• Humana
• Medicaid
• Medicare MCR
• Molina
• POMCO Group
• Thrivent Financial
• United Healthcare

Education

---

• Tulane University
• Hunan Medical University

Hospital

---

• Ohio State University Wexner Medical Center

Drug Facts

---

NPI NUMBER		1851505226
NPPES Provider LastName		ZHAO
NPPES Provider FirstName		WEIQIANG
NPPES Provider ZIPCode		432402000
NPPES Provider State		OH
Specialty Description		Pathology
Total Claim Count		16.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1851505226
Last Name Of The Provider	ZHAO
First Name Of The Provider	WEIQIANG
View All

Similar Doctors

---

	Dr. Hari M. Sharma, MD This Doctor is OpenDoctor Recommended.
	Dr. Daniel Boue, MD This Doctor is OpenDoctor Recommended.
	Dr. Rolf F. Barth, MD
	Dr. Gary E. Barnett, MD This Doctor is OpenDoctor Recommended.
	Dr. Gerard J. Nuovo, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Sergey V. Brodsky, MD This Doctor is OpenDoctor Recommended.
	Dr. Sara B. Peters, MD This Doctor is OpenDoctor Recommended.
	Dr. Joan E. Durbin, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Paul E. Wakely Jr., MD This Doctor is OpenDoctor Recommended.
	Dr. Gordon N. Shecket, MD This Doctor is OpenDoctor Recommended.
	Dr. James M. Uhlenbrock, MD This Doctor is OpenDoctor Recommended.
	Dr. Brett W. Hendrickson, MD This Doctor is OpenDoctor Recommended.
	Dr. Noman I. Malik, MD This Doctor is OpenDoctor Recommended.
	Dr. Phyllis S. Hammond, MD This Doctor is OpenDoctor Recommended.
	Dr. Daniela M. Proca, MD This Doctor is OpenDoctor Recommended.
	Kathryn M. Clausen

---

Doctor Directory | TOS | twitter | FB | Angel | blog